title: The effect of topical cyclosporin on conjunctiva-associated lymphoid tissue (CALT).
abstract: Topical cyclosporin A is increasingly being used in the treatment of ocular surface immune-mediated disorders. The availability of the drug in oil-based vehicles or collagen shields has restricted its use because of ocular irritation or blurring of vision. Although topical cyclosporin is being used more frequently, its effect on the immunocompetent cells of the conjunctiva is not known. Our aim was to study the effect of cyclosporin instillation on the immunocomponent cells of conjunctiva-associated lymphoid tissue (CALT) of Lewis rat, using a novel method of topical drug delivery. A suspension of collagen bits impregnated with cyclosporin A was instilled into eyes of Lewis rats for 4 days (group 1) or 8 days (group 2). Control rats (group 3) received the suspension without cyclosporin. Frozen sections of eyelids and conjunctiva were immunostained with the following monoclonal antibody markers: W3/13 (CD3), W3/25 (CD4, macrophages), OX-8 (CD8), MARD-3 (B cells), ED1, ED2 (macro/monocytes), OX-6 (class II MHC, Ia) and OX-39 (CD25, IL-2 receptor). Intraepithelial (IE) and substantia propria cells for each subset were counted and expressed as numbers per section. By day 8, intraepithelial and substantia propria cells for all the above markers, except B cells, showed a significant reduction in numbers. The p values were < 0.02 for W3/13 (CD3), W3/25 (CD4), OX-8 (CD8), OX-39 (CD25) (IE only), ED1, ED2 and OX-6 positive cells. Goblet cells of control animals showed strong positive reaction with OX-39 (CD25) antibody. This was completely abolished following 8 days of topical cyclosporin. This study demonstrated that topical cyclosporin A induces a marked reduction in numbers of all subtypes of immunocompetent cells in the conjunctival epithelium and substantia propria.
authors.affiliation: Department of Ophthalmology, Nottingham University, UK.
authors.forename: H S
authors.initials: HS
authors.lastname: Dua
authors.forename: V K
authors.initials: VK
authors.lastname: Jindal
authors.forename: J A
authors.initials: JA
authors.lastname: Gomes
authors.forename: W A
authors.initials: WA
authors.lastname: Amoaku
authors.forename: L A
authors.initials: LA
authors.lastname: Donoso
authors.forename: P R
authors.initials: PR
authors.lastname: Laibson
authors.forename: K
authors.initials: K
authors.lastname: Mahlberg
mesh_terms: D000287:Administration, Topical; D000818:Animals; D003094:Collagen; D003228:Conjunctiva / Q000187:drug effects* / Q000276:immunology; D016572:Cyclosporine / Q000008:administration & dosage / Q000494:pharmacology*; D004337:Drug Carriers; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D008221:Lymphoid Tissue / Q000187:drug effects* / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew
chemical_list: D004337:Drug Carriers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003094:Collagen